Literature DB >> 15860864

Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer.

Arnstein Mykletun1, Alv A Dahl, Carl Fredrik Haaland, Roy Bremnes, Olav Dahl, Olbjørn Klepp, Erik Wist, Sophie D Fosså.   

Abstract

PURPOSE: The prevalence of long-term survivors after treatment for testicular cancer (TC) is increasing, and most studies display normal or only slightly reduced quality of life (QOL) in TC survivors (TCSs). Impaired QOL is claimed to be associated with treatment modality and its side effects, although most studies in this field can be criticized for various methodologic shortcomings. We wanted to examine variation in long-term QOL in TCSs in relation to TC treatment modality, side effects, and TC-related stress in a large population. PATIENTS AND METHODS: QOL, side effects, and TC-related stress were self-rated by a questionnaire at a mean of 11 years of follow-up in 1,409 TCSs treated from 1980 to 1994. Norm data was obtained from 2,678 males who were representative of the general population. QOL was measured with the Short Form-36 (SF-36), and TC-related stress was measured with the Impact of Event Scale.
RESULTS: There were no clinically relevant differences in QOL between TCSs and age-adjusted norm data, although there was a slightly lowered SF-36 Physical Component Summary Score in TCSs. Variation of QOL in TCSs was related to self-reported side effects and TC-related stress but not to TC treatment modality. A significant association was found between side effects and TC-related stress.
CONCLUSION: TCSs do not suffer long term from reduced QOL, and only minor differences in QOL were found between different treatment modalities. TCSs who report more side effects or TC-related stress have increased risk for reduced QOL, but these associations are not explained by TC treatment modalities. Further QOL research in this area should explore vulnerability factors for side effects and TC-related stress.

Entities:  

Mesh:

Year:  2005        PMID: 15860864     DOI: 10.1200/JCO.2005.08.048

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors.

Authors:  Christian Falk Dahl; Hege Sagstuen Haugnes; Roy Bremnes; Olav Dahl; Sophie D Fosså; Olbjørn Klepp; Erik Wist; Alv A Dahl
Journal:  J Cancer Surviv       Date:  2010-06-24       Impact factor: 4.442

2.  Quality of life among testicular cancer survivors: a case-control study in the United States.

Authors:  Christopher Kim; Katherine A McGlynn; Ruth McCorkle; Ralph L Erickson; David W Niebuhr; Shuangge Ma; Barry Graubard; Briseis Aschebrook-Kilfoy; Kathryn Hughes Barry; Yawei Zhang
Journal:  Qual Life Res       Date:  2011-04-17       Impact factor: 4.147

3.  The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study.

Authors:  Allan Ben Smith; Phyllis Butow; Ian Olver; Tim Luckett; Peter Grimison; Guy C Toner; Martin R Stockler; Elizabeth Hovey; John Stubbs; Sandra Turner; George Hruby; Howard Gurney; Mahmood Alam; Keith Cox; Madeleine T King
Journal:  J Cancer Surviv       Date:  2015-07-16       Impact factor: 4.442

4.  Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey.

Authors:  Jacqueline L Bender; David Wiljer; Matthew J To; Philippe L Bedard; Peter Chung; Michael A S Jewett; Andrew Matthew; Malcolm Moore; Padraig Warde; Mary Gospodarowicz
Journal:  Support Care Cancer       Date:  2012-03-03       Impact factor: 3.603

5.  Differential Impact of Symptom Prevalence and Chronic Conditions on Quality of Life in Cancer Survivors and Non-Cancer Individuals: A Population Study.

Authors:  I-Chan Huang; Melissa M Hudson; Leslie L Robison; Kevin R Krull
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-23       Impact factor: 4.254

6.  Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Authors:  Chunkit Fung; Howard D Sesso; Annalynn M Williams; Sarah L Kerns; Patrick Monahan; Mohammad Abu Zaid; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Christian K Kollmannsberger; Ryan Cook; Sandra Althouse; Shirin Ardeshir-Rouhani-Fard; Steve E Lipshultz; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis
Journal:  J Clin Oncol       Date:  2017-02-27       Impact factor: 44.544

Review 7.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

8.  Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.

Authors:  Sumanta K Pal; Jonathan Yamzon; Virginia Sun; Courtney Carmichael; Junmi Saikia; Betty Ferrell; Paul Frankel; Joann Hsu; Przemyslaw Twardowski; Cy A Stein; Kim Margolin
Journal:  Clin Genitourin Cancer       Date:  2012-10-11       Impact factor: 2.872

9.  Dismantling the present and future threats of testicular cancer: a grounded theory of positive and negative adjustment trajectories.

Authors:  Lauren Matheson; Mary Boulton; Verna Lavender; Andrew Protheroe; Sue Brand; Marta Wanat; Eila Watson
Journal:  J Cancer Surviv       Date:  2015-07-10       Impact factor: 4.442

10.  Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.

Authors:  Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså
Journal:  J Natl Cancer Inst       Date:  2009-12-16       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.